Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.

Autor:	Lam C; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA., Ha K; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA., Hakam A; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Shahzad MMK; Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Oncologic Sciences, University of South Florida, Morsani School of Medicine, Tampa, FL, USA.
Jazyk:	angličtina
Zdroj:	Gynecologic oncology reports [Gynecol Oncol Rep] 2022 May 02; Vol. 41, pp. 100992. Date of Electronic Publication: 2022 May 02 (Print Publication: 2022).
DOI:	10.1016/j.gore.2022.100992
Abstrakt:	•Management of platinum refractory ovarian cancer is challenging.•Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy.•Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu